Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 8-K (Current Report)
Date of Report: April 27, 2005
Reporting Period: Second fiscal quarter of fiscal year 2005
This filing announces the issuance of a press release containing financial results for the second fiscal quarter of 2005. The report also details specific legal developments and outlines the company's methodology for presenting non-GAAP financial measures.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the text of this 8-K.
Non-GAAP Measures: Management presents adjusted financial measures to facilitate period-to-period comparisons. Adjustments include:
- Revenue growth rates calculated at constant foreign exchange rates.
- Earnings per share (EPS), gross profit, operating income, and net income excluding significant charges and unusual/non-recurring items.
- Exclusion of share-based compensation expense impacts where prior periods did not recognize such expense.
- Exclusion of effects from changes in tax laws, regulations, and rate changes on EPS and effective tax rates.
Material Changes and Legal Developments
Legal Proceedings:
- Qui Tam Action Dismissed: On April 15, 2005, the U.S. District Court for the Northern District of Texas dismissed without prejudice a proposed qui tam action against BD under the Federal False Claims Act.
- New Litigation: On April 21, 2005, Dynovation Medical, Inc. filed a lawsuit against BD in the U.S. District Court for the Eastern District of Texas. Plaintiffs allege material breach of a license agreement regarding the Insyte Autoguard IV catheter and patent infringement regarding safety blood collection sets. Plaintiffs seek monetary damages and injunctive relief. BD intends to vigorously defend the suit, asserting the allegations are without merit.
Guidance, Outlook, and Management Commentary
Management Commentary: Management utilizes the disclosed non-GAAP measures for internal performance evaluation, budget planning, and to provide investors with insight into underlying operational performance by removing the impact of currency fluctuations, significant charges, and tax law changes.
Limitations: The filing explicitly states that non-GAAP results should not be considered in isolation or as a substitute for GAAP results. Management acknowledges that excluded items may materially impact net income and cash flows.
Guidance: The filing text does not contain specific forward-looking guidance or numerical outlook for future periods.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP financial figures for Q2 2005.
- Verify the magnitude of "significant charges" and "unusual items" excluded from non-GAAP calculations to assess their impact on GAAP net income.
- Monitor the status of the Dynovation Medical, Inc. lawsuit for potential financial exposure or operational restrictions.
- Confirm the impact of foreign exchange rate fluctuations on reported revenue growth by comparing constant currency vs. reported growth rates in the press release.